Blog

Brandon Sheffield: Canadian Expert Consensus on Predictive Biomarker Testing in Gastric and GEJ Adenocarcinoma

cancerhealth.com

Dec 13, 2024, 16:02

Brandon Sheffield: Canadian Expert Consensus on Predictive Biomarker Testing in Gastric and GEJ Adenocarcinoma

Brandon Sheffield, Diagnostic and Molecular Pathologist at William Osler Health System, shared on LinkedIn:

“Great new resource for pathologists and oncologists!

A lot has changed in gastric cancer, we have a lot of new therapies to offer. Pathologists are playing a big part here with Claudin18 becoming the latest IHC biomarker coming into play for precision medicine in gastric cancer patients.

Read on to see some helpful recommendations from Canadian pathologists and oncologists.”

Canadian Consensus Recommendations for Predictive Biomarker Testing in Gastric and Gastroesophageal Junction Adenocarcinoma

Authors: Christine Brezden-Masley, Pierre O. Fiset, Carol C. CheungThomas Arnason, Justin Bateman, Martin Borduas, Gertruda Evaristo, Diana N. Ionescu, Howard J. Lim, Brandon S. Sheffield, Sara V. Soldera, Catherine J. Streutker

Brandon Sheffield: Canadian Expert Consensus on Predictive Biomarker Testing in Gastric and GEJ Adenocarcinoma

Brandon S. Sheffield Brandon Sheffield cancer Carol C. CheungThomas Arnason Catherine J. Streutker Christine Brezden-Masley Diana N. Ionescu Gertruda Evaristo Howard J. Lim Justin Bateman Martin Borduas OncoDaily Oncology Pierre O. Fiset Sara V. Soldera

Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity